GeneBioTech Co. ,Ltd (KOSDAQ: 086060)

GeneBioTech Co. ,Ltd Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	10,509	8,751	7,430	7,430	8,794	5,624
Short-Term Investments	13,804	13,265	8,660	10,360	18,593	19,415
Cash & Short-Term Investments	24,313	22,016	16,090	17,790	27,387	25,039
Cash Growth	15.94%	36.83%	-9.56%	-35.04%	9.38%	-18.19%
Accounts Receivable	12,625	11,588	14,090	10,225	6,655	7,637
Other Receivables	191.63	180.69	183.82	74.85	80.37	127.81
Receivables	12,857	11,818	14,302	10,371	6,899	7,912
Inventory	17,754	14,802	15,452	13,676	10,441	10,739
Prepaid Expenses	17.13	24.16	25.66	41.05	44.35	118.11
Other Current Assets	636.5	621.38	399.76	298.05	698.85	54.24
Total Current Assets	55,577	49,281	46,269	42,175	45,470	43,862
Property, Plant & Equipment	13,694	14,159	14,615	14,900	12,910	18,769
Long-Term Investments	738.2	718.86	484.19	763.6	1,241	3,107
Goodwill	-	-	589.54	589.54	589.54	589.54
Other Intangible Assets	665.04	632.02	398.29	199.07	198.94	304.33
Long-Term Deferred Tax Assets	32.19	205.29	495.41	870.49	521.64	-
Other Long-Term Assets	487.94	513	666.71	294.23	376.97	383.65
Total Assets	71,653	66,017	64,041	60,368	62,085	67,933
Accounts Payable	3,699	3,540	3,901	4,752	1,671	2,709
Accrued Expenses	1,177	970.5	649.23	515.74	532.03	838.51
Short-Term Debt	11,007	7,704	9,486	8,042	4,352	2,738
Current Portion of Long-Term Debt	2,359	1,534	1,159	-	-	-
Current Portion of Leases	112.37	132.92	42.29	112.39	69.15	80.28
Current Income Taxes Payable	73.43	284.27	14.46	-	237.89	231.33
Current Unearned Revenue	-	-	-	-	1.96	2.08
Other Current Liabilities	371.11	347.33	667.94	716.5	815.97	3,342
Total Current Liabilities	18,800	14,513	15,920	14,139	7,680	9,942
Long-Term Debt	2,145	2,995	2,329	2,113	1,113	14,491
Long-Term Leases	135.14	135.08	12.35	33.57	68.66	15.32
Long-Term Deferred Tax Liabilities	45.19	-	-	-	-	55.96
Other Long-Term Liabilities	73.15	68.54	53.02	137	2,795	98.2
Total Liabilities	21,199	17,712	18,315	16,423	11,657	24,602
Common Stock	4,305	4,305	4,305	4,305	4,305	4,305
Additional Paid-In Capital	14,576	14,576	14,576	14,489	14,835	14,800
Retained Earnings	31,203	29,059	18,116	16,190	16,844	19,303
Comprehensive Income & Other	370.53	364.07	8,729	8,961	9,059	8,521
Total Common Equity	50,455	48,305	45,726	43,945	45,043	46,929
Minority Interest	-	-	-	-	-	-3,598
Shareholders' Equity	50,455	48,305	45,726	43,945	50,428	43,331
Total Liabilities & Equity	71,653	66,017	64,041	60,368	62,085	67,933
Total Debt	15,759	12,502	13,029	10,302	5,603	17,324
Net Cash (Debt)	8,553	9,514	3,061	7,488	21,784	7,714
Net Cash Growth	29.55%	210.80%	-59.12%	-65.62%	182.38%	-44.94%
Net Cash Per Share	993.34	1104.91	355.50	869.68	2529.89	895.90
Filing Date Shares Outstanding	8.61	8.61	8.61	8.61	8.61	8.61
Total Common Shares Outstanding	8.61	8.61	8.61	8.61	8.61	8.61
Working Capital	36,778	34,768	30,349	28,037	37,791	33,920
Book Value Per Share	5859.62	5609.93	5310.44	5103.62	5231.12	5450.16
Tangible Book Value	49,790	47,673	44,738	43,157	44,255	46,035
Tangible Book Value Per Share	5782.39	5536.52	5195.72	5012.04	5139.55	5346.35
Land	7,011	7,061	5,464	5,464	4,115	4,120
Buildings	6,452	6,533	6,489	6,471	4,101	10,427
Machinery	9,594	9,342	9,255	9,222	9,140	17,917
Construction In Progress	82.27	41.65	1,620	1,007	1,935	1,793

Source: S&P Capital IQ. Standard template. Financial Sources.